A previous study demonstrated that targeting TNFR2 with antagonistic antibodies inhibits the proliferation of ovarian cancer cells and tumor-associated Tregs, implying the therapeutic potential of anti-TNFR2 antibody in tumor immunotherapy (Torrey et al., 2017). This evidence concerns the gene TNFRSF1B and ovarian carcinoma.